

REFERENCES

- Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AI, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, PooleL, Stolzenbach JC and Creasey AA (2003):** Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. *JAMA*; 290(2): 256-8.
- Abudu N, Levinson S and Miller J (2003):** Triglycerides/HDL-c levels versus ApoA-1₁ and apoB in Coronary Artery Disease (CAD) for recognition of Familial Combined Hyperlipidemia (FCH). *Journal of the American Diabetes Association*; 52 (1): F67.
- Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996):** Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 271:518-520.
- Aderem, A and Ulevitch, RJ (2000):** Toll-like receptors in the induction of the innate immune response. *Nature* 406, 782–787.
- Afroza S (2006):** Neonatal sepsis-a global problem: an overview. *Mymensingh Med J*; 15(1): 108-14.
- Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2002):** Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. *Biochem Biophys Res Commun* 290:391-396.

- Airoidi J, Berghella V (2006):** Hepatitis C and pregnancy. *Obstet Gynecol Surv.* Oct;61(10):666-72.
- Alberti, C. et al (2002):** Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Med.* **28**, 108–121.
- Alvarez C and Ramos A (1986):** Lipids, lipoproteins, and apoproteins in serum during infection. *Clin Chem* 32:142-145.
- American Academy of pediatrics (2000):** Red book 25th ed., 530-590.
- Angus, D. C. et al (2001):** Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit. Care Med.* **29**, 1303–1310.
- Anname, D et al. (2002)** Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *J. Am. Med. Assoc.* 288, 862–871.
- Antenatal care (2008):** Routine care for the healthy pregnant woman, NICE Clinical Guideline (March).
- Assman G (1988):** Triglycerides and atherosclerosis. *Lipid Rev*; 2: 89-96.
- Assmann G and Brewer HB Jr (1974):** A molecular model of high density lipoproteins. *Proc Natl Acad Sci USA* 71:1534-1538.
- Auriti C, Maccallini A, Diliso D et al. (2003):** Risk factors for nosocomial infection in a neonatal Intensive Care Unit. *J Hosp Infect*; 53 (1):25-30.

Austgulen R, Arntzen KJ, Haereid PE, Aag S, and Dollner H (1997): Infections in neonates delivered at term are associated with increased serum levels of ICAM-1 and E-selectin. *Acta Paediatrica*; 86 (3): 274-80.

Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Eroglu J, Hsu C, Dunlop C (1998): La Du BN. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. *Arterioscler Thromb Vasc Biol* 18:1617-1624.

Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000): Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. *Circulation* 101:2510-2517.

Ballard JK, Khoury JC, Wedig K, et al (1991): New Ballard Score, expanded to include extremely premature infant. *J Pediatr*; 119:417.

Baltimore R (1998): Neonatal nosocomial infection. *Semin. Perinatal*; 22 (1):25-32.

Banatvala JE, Brown DW (2004): Rubella.; Lancet. Apr 3; 363 (9415): 1127-37.

Baquero Latorre H, Neira Safi F and Gonzalez Vargast (2006): Endogenous endophthalmitis due to *Serratia marcescens* in the course of early neonatal sepsis. An Pediatr; 64 (3):291-2.

Barlage S, Frohlich D, Bottcher A, Jauhiainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G (2001): ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 42:281-290.

Bauer, S. et al. (2001): Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237–9242.

Baumberger C, Ulevitch RJ, Dayer JM (1991): Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 59:378-383.

Beckstead JA, Oda MN, Martin DD, Forte TM, Bielicki JK, Berger T, Luty R, Kay CM, Ryan RO (2003): Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry 42:9416-9423.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001): Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 344:699-709.

Bernard, GR et al. (2001): Efficacy and safety of recombinant human activated protein C for severe sepsis. *N. Engl. J. Med.* 344, 699–709.

Berner R, Tuven B, Clad A and Brandis M (2000): Elevated gene expression of interleukin-8 in cord blood is a sensitive marker for neonatal sepsis. *Eur.J Pediatr*; 159 (3): 205-10.

Bhutta K and Yusu F (1997): Neonatal sepsis in Karachi: Factors determing outcome and mortality. *J Trop Pediatr*; (43): 65-70.

Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J (2001): Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. *J Lipid Res* 42: 1727-1739.

Blank C, Luz A, Bendigs S, Erdmann A, Wagner H, Heeg K (1997): Superantigen and endotoxin synergize in the induction of lethal shock. *Eur J Immunol* 27:825-833.

- Bochkov, VN et al. (2002):** Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. *Nature* 419, 77–81.
- Boisfer E, Stengel D, Pastier D, Laplaud PM, Dousset N, Ninio E, Kalopissis AD (2002):** Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. *J Lipid Res* 43:732-741.
- Bosisio, D et al. (2002):** Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. *Blood* 99, 3427–3431.
- Bouchon, A, Dietrich, J, Colonna, M (2000):** Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. *J. Immunol.* 164, 4991–4995.
- Bouchon, A, Facchetti, F, Weigand, MA, Colonna, M (2001):** TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature* 410, 1103–1107.
- Bowie, A and O'Neill, LA (2000):** The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. *J. Leukoc. Biol.* 67, 508–514.
- Bozza, M et al. (1999):** Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. *J. Exp. Med.* 189, 341–346.

- Brealey, D et al. (2002):** Association between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet* 360, 219–223.
- Breslow JL (1995):** Familial disorders of high-density lipoprotein metabolism. In: *The Metabolic and Molecular Bases of Inherited Disease*. 7th ed., Scriver CR, Beaud et al., Sly WS and Valle D (eds.). New York, McGraw-Hill; 2: 2031-52.
- Brew HB, Gregg RE and Hoeg JM et al. (1988):** Apolipoprotein A-1 and lipoproteins in human plasma. An overview. *Clin Chem*; 34: 4.
- Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO (1999):** Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. *Nature Genet* 22:336-345.
- Brunzell JD (1995):** Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: *The Metabolic and Molecular Bases of Inherited Diseases*, 7th ed. Scriver CR, Beaudet al., Sly WS and Valle D (eds). New York, McGraw-Hill; 2: 1913-32.
- Cabana VG, Siegel JN, Sabesin SM (1989):** Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. *J Lipid Res* 30:39-49.
- Calabresi L, Rossoni G, Gomaschi M, Berti F, Franceschini G (2003):** High-density lipoproteins protect rat hearts from ischemia-reperfusion injury by reducing cardiac TNF-content and enhancing prostaglandin release. *Circ Res* 92:330-337.

- Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP (2000):** Protection from septic shock by neutralization of macrophage migration inhibitory factor. *Nat Med* 6:164-170.
- Calandra, T et al. (1995):** MIF as a glucocorticoid-induced modulator of cytokine production. *Nature* 377, 68–71.
- Calandra, T, Spiegel, LA, Metz, CN, Bucala, R (1998):** Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. *Proc. Natl Acad. Sci. USA* 95, 11383–11388.
- Calvert GD and Abbey M (1985):** Plasma lipoproteins, apolipoproteins A-1nd proteins concerned with lipid metabolism. *Adv Chem*; 24: 217-98.
- Carl A, Burtis PhD and Edward R et al. (1999):** Lipids, lipoproteins and apolipoproteins. In: *Tietz Textbook of Clinical Chemistry*. Carl A, Burtis PhD, Edward R, Ashweod MD (eds.). WB Saunders Company, Philadelphia, London, Tokyo; 809-61.
- Chait A, Brazg RL, Tribble DL, Krauss RM (1993):** Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. *Am J Med* 94:350-356.
- Choe, KM, Werner, T, Stoven, S, Hultmark, D, Anderson, KV (2002):** Requirement for a peptidoglycanrecognition protein (PGRP) in Relish activation and antibacterial immune responses in *Drosophila*. *Science* 296, 359–362.

Claudio Chiesa, Alessandra Panero, John F.Osborn, Antonella F, Simonetti and Lucia Pacifico (2004): Diagnosis of neonatal sepsis: A clinical and laboratory challenge. *Clinical chemistry*; 50:279-287.

Cochrane Database of Systematic Reviews (2000), Issue 1. Art. No.: CD001971. DOI: 10.1002/14651858.CD001971.

Cochrane Database of Systematic Reviews (2003), Issue 2. Art. No.: CD004205. DOI: 10.1002/14651858.CD004205.

Cochrane Database of Systematic Reviews (2003), Issue 3. Art. No.: CD003066. DOI: 10.1002/14651858.CD003066.

Cochrane Database of Systematic Reviews (2003), Issue 4. Art. No.: CD003956. DOI: 10.1002/14651858.CD003956.

Cochrane Database of Systematic Reviews (2004), Issue 4. Art. No.: CD004495. DOI: 10.1002/14651858.CD004495.pub2.

Cochrane Database of Systematic Reviews (2006), Issue 1. Art. No.: CD005091. DOI: 10.1002/14651858.CD005091.pub2.

Cockerill GW and Reed S (1999): High-density lipoprotein: multipotent effects on cells of the vasculature. *Int Rev Cytol* 188:257-297.

Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO (2001): Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. *Circulation* 103:108-112.

- Cockerill GW, McDonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiernemann C (2001):** High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. *FASEB J* 15:1941-1952.
- Cockerill GW, Rye K-A, Gamble JR, Vadas MA, Barter PJ (1995):** High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. *Arterioscler Thromb Vasc Biol* 15:1987-1994.
- Cohen, J (1999):** Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. *Br. Med. Bull.* 55, 212–226.
- Cortelazzi D, Cappiello V, Morpurgo PS, Ronzoni S, Nobile De Santis MS, Cetin I, Beck. Peccoz P and Spada A (2003):** Circulating levels of ghrelin in human fetuses. *Eur J Endocrinol*; 149: 111-116.
- Cué JI, DiPiro JT, Brunner LJ, Doran JE, Blankenship ME, Mansberger AR, Hawkins ML (1994):** Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor responses to lipopolysaccharide in rabbits. *Arch Surg* 129:193-197.
- Cuschieri J, Gourlay D, Garcia I, Jelacic S, Maier RV (2003):** Modulation of endotoxin-induced endothelial function by calcium/calmodulin-dependent protein kinase. *Shock* 20:176-182.
- Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, De Sarro A, Van de Loo FA, Caputi AP, Thiernemann C (2002):** Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury. *Shock* 18:169-176.

- Daley AJ, Thorpe S, Garland SM (2008):** Varicella and the pregnant woman: prevention and management. *Aust N Z J Obstet Gynaecol.* Feb; 48 (1): 26-33.
- Daniel WW (1995):** Biostatistics: A foundation for analysis in the health sciences 6th edition. John Wiley and sons, Inc, New York.
- Dar-Shang L, Shing-Huey H, Chun-Chun L, Yi-Chen T, Tsu-Tzu H, Nan-Chang C, Hsin-An K, Han-Yang H, Chyong –Hsin H, Wen-Shyang H, Dien-Le-Y and Fu-Yuan H (2000):** Urinary Tract Infection in febrile infants younger than eight weeks of age. *Pediatrics*; 105(2): 20.
- Das DK (2003):** Cardioprotection with high-density lipoproteins: fact or fiction? *Circ Res* 92:258-260.
- Davis RA (1991):** Lipoprotein structure and secretion. In: *Biochemistry of Lipids, Lipoproteins and Membranes.* Vance DE and Vance J (eds). Elsevier Science Publishers, BV, Chapter 14.
- De Geest B, Stengel D, Landeloos M, Lox M, Le Gat L, Collen D, Holvoet P, Ninio E (2000):** Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. *Arterioscler Thromb Vasc Biol* 20:E68-E75.

- de Kimpe SJ, Thiemermann C, Vane JR (1995):** Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock. *Br J Pharmacol* 116:3191-3198.
- Devitt, A et al. (1998):** Human CD14 mediates recognition and phagocytosis of apoptotic cells. *Nature* 392, 505–509.
- Dhadly P, McDonald MC, Cockerill GW, Mota-Filipe H, Hinds CJ, Miller NE, Thiemermann C (2000):** High-density lipoprotein (HDL) reduces the renal injury and dysfunction in shock. In Faist E (ed.): *Proceedings of the 5th World Congress on Trauma, Shock, Inflammation and Sepsis-Pathophysiology, Immune Consequences and Therapy*. Italy: Monduzzi Editore, pp. 239-244.
- Di Bartolomeo S, Mirta DH, Janer M, et al (2001):** Incidence of Chlamydia trachomatis and other potential pathogens in neonatal conjunctivitis. *Int J Infect Dis*. 5(3):139-43
- Di Mario S, Basevi V, Gagliotti C, et al. (2009):** Prenatal education for congenital toxoplasmosis. *Cochrane Database Syst Rev*. Jan 21;(1):CD006171.
- Dinarello, CA (1997):** Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. *Chest* 112, 321S–329S.
- Dinges, MM and Schlievert, PM (2001):** Role of T cells and gamma interferon during induction of hypersensitivity to lipopolysaccharide by toxic shock syndrome toxin 1 in mice. *Infect. Immun.* 69, 1256–1264.

- DiPiro JT, Cue JI, Richards CS, Hawkins ML, Doran JE, Mansberger AR (1996):** Pharmacokinetics of reconstituted human high-density lipoprotein in pigs after hemorrhagic shock with resuscitation. *Crit Care Med* 4:440-444.
- Döcke, WD et al. (1997):** Monocyte deactivation in septic patients: restoration by IFN- γ treatment. *NatureMed.* 3, 678–681.
- Doellner H, Arntzen K, Haereid P and Aag S (1998):** Interleukin-6 concentrations in neonates evaluated for sepsis. *J Pediatr*; 132(2): 295-9.
- Draganov DI, Stetson PL, Watson CE, Billecke SS (2000):** La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. *J Biol Chem* 275:33435-33442.
- Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart JC, Castro G (1993):** Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. *Arterioscler Thromb* 13:126-132.
- Easterbrook PJ (1999):** Lipids and metabolism. In: *Basic Medical Sciences*. 2nd ed. Easterbrook (ed.). Churchill Livingstone, Harcourt Brace and Company Limited; 243-54.
- Eaves-Pyles, T et al. (2001):** Flagellin, a novel mediator of salmonella-induced epithelial activation and systemic inflammation: IkBa degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. *J. Immunol.* 166, 1248–1260.

- Eberly MD, Rajnik M (2009):** The effect of universal maternal screening on the incidence of neonatal early-onset group B streptococcal disease. Clin Pediatr (Phila). May;48(4):369-75. Epub 2008 Oct 2.
- Eggesbo JB, Hjermann I, Hostmark AT, Kierulf P (1996):** LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine 8:152-160.
- Eggesbo JB, Lyberg T, Aspelin T, Hjermann I, Kierulf P (1996):** Different binding of 125I-LPS to plasma proteins from persons with high or low HDL. Scand J Clin Lab Invest 56:533-543.
- Eisenberg S (1984):** High density lipoprotein metabolism. J Lipid Res 25:1017-1058.
- Emancipator K, Csako G, Elin RJ (1992):** In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immunol 60:596-601.
- Engle W, Rosenfield C, Mouzinko A. et al, (1997):** Circulating neutrophil in septic preterm neonates. Pediatrics; 99:1.
- Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, Verdery RB (1994):** Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 14:8-13.

- Fain JN, Bahouth SW and Madan AK (2004):** TNF- α Release by the non fat cells of human adipose tissue. *Int. J.Obes. Relat. Metab Disord*; 28 (4): 616-622.
- Farmer JA and Gotto AM (1992):** Risk factors for coronary artery disease. In: *Heart Disease: A Textbook of Cardiovascular Medicine*. 4th ed. Farmer JA and Gotto AM (eds.). WB Saunders Company, Philadelphia, London; 1124.
- Faust, SN et al. (2001):** Dysfunction of endothelial protein C activation in severe meningococcal sepsis. *N.Engl. J. Med.* 345, 408–416.
- Feingold KR and Grunfeld C (1987):** Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. *J Clin Invest* 80:184-190.
- Feingold KR, Hardardottir I, Memon R (1993):** Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. *J Lipid Res* 34:2147-2158.
- Feingold KR, Memon RA, Moser AH, Grunfeld C (1998):** Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. *Atherosclerosis* 139:307-315.
- Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C (1999):** Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. *Atherosclerosis* 142:379-387.

- Fielding CJ and Fielding PE (1995):** Molecular physiology of reverse cholesterol transport. *J Lipid Res* 36:211-228.
- Fisher Jr, CJ Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E (1996):** Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. *N Engl J Med* 334:1697-1702.
- Fowlie P and Schmidt B (1998):** Diagnosis test for bacterial infection from birth to 90th days. *Arch. Dis. Child. (Fetal Neonatal Edition)*; 78 (2):92-8.
- Froidevaux C, Roger T, Martin C, Glauser MP, Calandra T (2001):** Macrophage migration inhibitory factor and innate immune responses to bacterial infections. *Crit Care Med* 29 (7 Suppl):S13-S15.
- Gabay C and Kushner I (1999):** Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 340:448-454.
- Gallin JI, Kaye D, O'Leary WM (1969):** Serum lipids in infection. *N Engl J Med* 281:1081-1086.
- Gamble C, Ekwaru JP, ter Kuile FO (2006):** Insecticide-treated nets for preventing malaria in pregnancy. *Cochrane Database Syst Rev*. Apr 19; (2): CD003755.

- Garner P, Gulmezoglu AM (2006):** Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev. Oct 18; (4): CD000169.
- Gerald L, Marie B and Jean F et al. (2002):** Value of HDL-C, Apolipoprotein A-1₁, lipoprotein A₁ and lipoprotein A₁/A₁₁ in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol; 22(7): 1155-61.
- Gilbert GL (2002):** Infections in pregnant women.; Med J Aust. Mar 4;176(5):229-36.
- Giraudon I, Forde J, Maguire H, et al. (2009):** Antenatal screening and prevalence of infection: surveillance in London, 2000-2007. Euro Surveill. Mar 5;14(9):8-12.
- Glauser MP (1996):** The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs 52 (Suppl 2):9-17.
- Glew HR (2002):** Lipid metabolism. II. Pathways of metabolism of special lipids. In: Textbook of Biochemistry with Clinical Correlations. 5th ed. Devlin (ed). Wiley-Liss, New York, Chap.17; 728.
- Goldstein JL and Brown MS (1989):** The low density lipoprotein receptor pathway and its relation to atherosclerosis. Ann Rev Biochem; 46: 897-930.

- Gomella TL, Cunningham MD, Eyal FG and Zenk KE (1999):** Infectious Diseases. In: Gomella T.L., Editor. Neonatology. Stamford, Connecticut: Appleton, Lange; 408-414.
- Gong M, Wilson M, Kelly T, Su W, Dressman J, Kincer J, Matveev SV, Guo L, Guerin T, Li XA, Zhu W, Uittenbogaard A, Smart EJ (2003):** HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 111:1579-1587.
- Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ (1996):** Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 24:584-589.
- Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, Barie PS, Rubin AL (2001):** Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 29:1563-1568.
- Gottar, M et al. (2002):** The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein. Nature 416, 640–644.
- Gottof SP (2000):** Infections of the Neonatal Infant. In: Nelson Textbook of Pediatrics. Behrman R.E., Kleigman R.M. and Jenson H.B.(eds) 16th Edition, WB Saunders Company. Pp.538-552.

- Gowenlock AH, McMurray JR and McLauchlan DM (2002):** Lipids and lipoproteins. In: Varley's Practical Clinical Biochemistry. 6th ed. Gowenlock AH, McMurray JR and McLauchlan DM (eds.). CBS Publishers and Distributors, India, Chap.21; 454-5.
- Grant HW and Hadley GP (1997):** Prediction of neonatal sepsis by thromboelastography. *Pediatric Surgery International*; 12(4): 289-92.
- Griffian M and Moorman J (2001):** Toward the early diagnosis of neonatal sepsis and sepsis-like illness using novel heart rate analysis. *Pediatr*; 107(1): 97-104.
- Griffin JH, Zlokovic B, Fernandez JA: Activated protein C (2002):** potential therapy for severe sepsis, thrombosis, and stroke. *Semin Hematol* 39:197-205.
- Grunfeld C, Dinarello CA, Feingold KR (1991):** Tumor necrosis factor-alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. *Metabolism* 40:894-898.
- Grunfeld C, Marshall M, Shigenaga JK, Moser AH (1999):** Tobias P Feingold KR. Lipoproteins inhibit macrophage activation by lipoteichoic acid. *J Lipid Res* 40:245-252.
- Guerina NG (1998):** Bacterial and Fungal infection: By Cloherty J.P. and Stark A.R.(eds). In *Manual of Neonatal Carc.*, 4th ed., Lippincott-Raven Publishers, Philadelphia, NewYork pp.271-300.

- Guida J, Runing A, Leaf K et al. (2003):** Platelet count and sepsis, is there an organism specific response. *Pediatrics*; 11: 310-315.
- Gursky O and Atkinson D (1996):** High- and low-temperature unfolding of human high-density apolipoprotein A-2. *Protein Sci* 5:1874-1882.
- Hailman E, Albers J, Wolfbauer G, Tu AY, Wright SD (1996):** Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. *J Biol Chem* 271:12172-12178.
- Haley M, Cuix, Minneci PC, Deans KJ, Natanson C and Eichacker PQ (2004):** Recombinant human activated Protein C in sepsis: assessing its clinical use. *Am J Med Sci*; 328 (4): 215-9.
- Hampe, J et al. (2002):** Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. *Lancet* 359, 1661–1665.
- Hardardóttir I, Kunitake ST, Moser AH (1994):** Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. *J Clin Invest* 94:1304-1309.
- Hardardottir I, Sipe J, Moser AH, Fielding CJ, Feingold KR, Grunfeld C (1997):** LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. *Biochim Biophys Acta* 1344:210-220.

- Harris HW, Grunfeld C, Feingold KR, Rapp JH (1990):** Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. *J Clin Investig* 86:696-702.
- Harris HW, Johnson JA, Wigmore SJ (2002):** Endogenous lipoproteins impact the response to endotoxin in humans. *Crit Care Med* 30:23-31,.
- Havel RJ, Goldstein JL and Brown MS (1980):** Lipoproteins and lipid transport. In: *Metabolic Control and Disease*. Bondy and Rosenberg LK (eds). Philadelphia, WB Saunders; 393-494.
- Hayashi, F et al. (2001):** The innate immune response to bacterial flagellin is mediated by Toll- like receptor 5. *Nature* 410, 1099–1103.
- Hayat S, Raynes JG (2000):** Acute phase serum amyloid A protein increases high density lipoprotein binding to human peripheral blood mononuclear cells and an endothelial cell line. *Scand J Immunol* 51:141-146.
- Hegele R: J.A. Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJ, Connelly PW (1993):** Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. *Arterioscler Thromb* 13:720-728.
- Heng CK, Low PS and Saha N (2001):** Variations in the promoter region of the Apolipoprotein A-1₁ gene influence plasma lipoprotein (a) levels in Asian Indian neonates from Singapore. *Pediatr Res*; 49: 514-8.

- Herwald, H et al. (1998):** Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases. *Nature Med.* 4, 298–302.
- Hickey MJ, Sharkey KA, Sihota EG, Reinhardt PH, MacMicking JD, Nathan C, Kubes P (1997):** Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. *FASEB J* 11:955-964.
- Hintz SR, Kendrick DE, Stoll BJ, Voehr BR, Fanaroff AA, Donovan EF, Poole WK, Blakely ML, Wright L and Higgins R (2005):** Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. *NICHD Neonatal Research network. Pediatrics;* 115(3):696-703.
- Hobbs HH, Rader DJ (1999):** ABC1: connecting yellow tonsils, neuropathy, and very low HDL. *J Clin Invest* 104:1015-1017.
- Hoffman DJ and Haris MC (1996):** Diagnosis of neonatal sepsis. In Spitzer AR,(editor): *Intensive care of fetus and neonate.* Mosby-year book, Boston-London- Toronto-Wiesbaden- Tokyo; 940-950.
- Hoffman JS and Benditt EP (1982):** Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high-density lipoprotein in primary mouse hepatocyte culture. *J Biol Chem* 257:10518-10522.

- Hotchkiss, RS et al. (1999):** Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit. Care Med.* 27, 1230–1251.
- Hotchkiss, RS et al. (1999):** Prevention of lymphocyte cell death in sepsis improves survival in mice. *Proc. Natl Acad. Sci. USA* 96, 14541–14546.
- Hotchkiss, RS et al. (2001):** Sepsis-induced apoptosis causes progressive profound depletion of B and CD4⁺T lymphocytes in humans. *J. Immunol.* 166, 6952–6963.
- Hubsch AP, Casas AT, Doran JE (1995):** Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteraemia models. *J Lab Clin Med* 126:548-558.
- Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, Seidman CE, Tremaroli JD, Lai J, Rubin AL (2003):** A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. *J Lipid Res* 44:1489-1498.
- Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA (1995):** Platelet-activating factor: a mediator for clinicians. *J Intern Med* 238:5-20.
- Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR (1990):** Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. *N Engl J Med* 323:1234-1238.

- Inohara, N, Ogura, Y, Chen, FF, Muto, A, Nunez, G (2001):** Human Nod1 confers responsiveness to bacterial lipopolysaccharides. *J. Biol. Chem.* 276, 2551–2554.
- Inohara, N, Ogura, Y, Nunez, G (2002):** Nods: a family of cytosolic proteins that regulate the host response to pathogens. *Curr. Opin. Microbiol.* 5, 76–80.
- Ismail S, Safaa S I, Kareem YS and Nahed NR (2002):** Clinical utility of adrenomedullin and Tumour Necrosis Factor-Alpha in neonatal sepsis. *Egyptian Journal of Pediatrics*; 19 (4): 597-610.
- Jamieson DJ, Read JS, Kourtis AP, et al. (2007):** Cesarean delivery for HIV-infected women: recommendations and controversies. *Am J Obstet Gynecol.* Sep; 197 (3 Suppl):S96-100.
- Janeway, C. A. Jr and Medzhitov, R (1998):** Introduction: the role of innate immunity in the adaptive immuneresponse. *Semin. Immunol.* 10, 349–350.
- Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR (1999):** Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. *J Clin Invest* 103:907-914.
- Jincharadze N, Abelashvili D, Mc Hedlishvili M and Kacharava M (2006):** Diagnostic value of C-reactive protein test as early-onset sepsis in preterm infants. *Goorgian Med News*; (30): 87-91.

- Jonas A, Hefele Wald J, Harms Toohill K, Krul ES, Kezdy KE (1990):** Apolipoprotein A-I structure and lipid properties in homogeneous reconstituted spherical and discoidal high density lipoproteins. *J Biol Chem* 265:22123-22129.
- Kaftan H and Kinney S (1998):** Early onset neonatal bacterial infections. *Seminars in Perinatology*; 22(1):15-24.
- Kaminska M, Badzio T, Ksiezopolska-Kaczorowska A, Bako W, Boj E, Przymanowski Z (1983):** High-molecular-weight lipoprotein concentrations in pneumonia in children. *Problem Med Wieku Rozwoj* 12:363-375.
- Kawakami M and Cerami A (1981):** Studies of endotoxin-induced decrease in lipoprotein lipase activity. *J Exp Med* 154:631-639.
- Kengatharan M, de Kimpe S, Robson C, Foster SJ, Thiernemann C (1998):** Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. *J Exp Med* 188:305-315.
- Kengatharan M: de Kimpe SJ, Thiernemann C (1996):** Analysis of the signal transduction in the induction of nitric oxide synthase by lipoteichoic acid in macrophages. *Br J Pharmacol* 117:1163-1170.
- Kennon C, Overtur G, Sierra et al (1996):** Granulocytes Colony Stimulating Factor as a marker for bacterial infection in neonates. *J Pediatr*; 128: 765-769.

- Kerur BM, Vishnu Bhat B, Harish BN, Habeebullah S, Uday Kumar C (2006):** Maternal genital bacterial and surface colonization in early neonatal sepsis. *Indian J Pediatr*; 73(1):29-32.
- Khosla SN, Goyle N, Seth RK (1991):** Lipid profile in enteric fever. *J Assoc Phys India* 39:260-262.
- Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C (2000):** Infection and inflammation-induced proatherogenic changes of lipoproteins. *J Infect Dis* 181(Suppl 3):S462-S472.
- Kirschning CJ, Au-Young J, Lamping N, Reuter D, Pfeil D, Seilhamer JJ, Schumann RR (1997):** Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins. *Genomics* 46:416-425.
- Kisilevsky R and Subrahmanyam L (1992):** Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. *Lab Invest* 66:778-785.
- Kisilevsky R, Lindhorst E, Ancsin JB, Young D, Bagshaw W (1996):** Acute phase serum amyloid A (SAA) and cholesterol transport during acute inflammation: A hypothesis. *Amyloid: Int J Exp Clin Invest* 3:252-260.
- Kitamura A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, Sato S, Kiyama M, Nakamura M, Sankai T (1994):** High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. *Circulation* 89:2533-2539.

- Kitchens RL and Thompson PA (2003):** Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins. *J Endotoxin Res* 9:113-118.
- Klein O J and Marcy SM (1995):** Bacterial Sepsis and Meningitis In the Infectious Disease of the fetus and Newborn. Klein and Remington (eds).
- Kotb, M (1995):** Bacterial pyrogenic exotoxins as superantigens. *Clin. Microbiol. Rev.* 8, 411–426.
- Kourtis AP, Jamieson DJ, de Vincenzi I, et al. (2007):** Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. *Am J Obstet Gynecol. Sep; 197 (3 Suppl):S113-22.*
- Krauss RM, Perlman JA and Petitti D (1988):** Effects of estrogen dose and smoking on lipid and lipoprotein levels in the postmenopausal women. *Am J Obstet Gynecol; 158: 1606-11.*
- Kravetz JD, Federman DG (2005):** Toxoplasmosis in pregnancy. *Am J Med.* 118 (3): 212-6
- Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990):** Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. *Nature* 344:160-162.

Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J (1997): The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. *J Lipid Res* 38:191-205.

Kunitake ST, Jarvis MR, Hamilton RL, Kane JP (1992): Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. *Proc Natl Acad Sci USA* 89:6993-6997.

Kwiterovich PO Jr (2000): The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. *Am J Cardiol* 86:5L-10L.

Lagrost L, Desrumaux C, Masson D, Deckert V, Gamber P (1998): Structure and function of the plasma phospholipid transfer protein. *Curr Opin Lipidol* 9:203-209.

Lambert G, Sakai N, Vaisman BL, Neufeld EB, Marteyn B, Chan CC, Paigen B, Lupia E, Thomas A, Striker LJ (2001): Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. *J Biol Chem* 276:15090-15098,.

Landmann, R. et al. (1995): Increased circulating soluble CD14 is associated with high mortality in Gramnegativesepsis shock. *J. Infect. Dis.* 171, 639–644.

- Landry, DW and Oliver, JA (2001):** The pathogenesis of vasodilatory shock. *N. Engl. J. Med.* 345, 588–595.
- Lavoie, PM, Thibodeau, J, Erard, F, Sekaly, RP (1999):** Understanding the mechanism of action of bacterial superantigens from a decade of research. *Immunol. Rev.* **168**, 257–269.
- Law YL and Hey EN (1991):** Sensitivity and specificity of daily tracheal aspirate culture in predicting organisms causing bacteremia in ventilated neonates. *Pediatr Infect Dis J*; 10(4):290-294.
- Leng X, Wang C, Song L. Lix, Ma J and Wang P (2003):** Generation of recombinant human tissue factor pathway inhibitor in *E.coli*. *Sheng Wuyi, Xue Gong Chang Xue Za Zhi*; 20(2): 314-7.
- Leroy JLC and Leroy OPR (1995):** Evaluation of a rapid slide latex agglutination assay for the qualitative and semi-quantitative determination of C-reactive protein in human serum. *Advanced Diagnostic Testing*; 10:1.
- Leturcq, DJ et al. (1996):** Antibodies against CD14 protect primates from endotoxin-induced shock. *J. Clin. Invest.* 98, 1533–1538.
- Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ (2003):** Distribution and kinetics of lipoprotein-bound lipoteichoic acid. *Infect Immun* 71:3280-3284.
- Levels JH, Abraham PR, van den Ende A, van Deventer SJ (2007):** Distribution and kinetics of lipoprotein-bound endotoxin. *Infect Immun* 69:2821-2828.

- Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ (2003):** Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. *Crit Care Med* 31:1647-1653.
- Levi, M and tenCate, H (1999):** Disseminated intravascular coagulation. *N. Engl. J. Med.* 341, 586–592.
- Levine DM, Parker TS, Donnelly TM, Walsh WM, Rubin AL (1993):** In vivo protection against endotoxin by plasma high density lipoprotein. *Proc Natl Acad Sci USA* 90:12040-12044.
- Linda B (2002):** Neonatal sepsis, the Scientific basis for Practice. *Neonatal network*; 10 (5): 10-40.
- Linda L and Bryan L (2004):** Track coordinator, Instructor, Neonatal Nurse Practitioner Program, Medical university of South Carolina, College of Nursing.
- Liu, C, Xu, Z, Gupta, D, Dziarski, R (2001):** Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules. *J. Biol. Chem.* 276, 34686–34694.
- Lodfors L, Y Tessin L, Mattson L, Fall D and Ericksson M (1998):** Risk factors for neonatal sepsis in offspring of women with PROM at 34-42 wks. *J Perinat Med*; 26 (2):94-101.

- Lorenz, E, Mira, JP, Cornish, KL, Arbour, NC, Schwartz, DA (2000):** A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. *Infect. Immun.* 68, 6398–6401.
- Lorenz, E, Mira, JP, Frees, KL, Schwartz, DA (2002):** Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. *Arch. Intern. Med.* 162, 1028–1032.
- Lott W (2003):** Neonatal bacterial sepsis. *Crit Care Nurse Clin North AM*; 15 (1): 35-36.
- Lu S, Yao Y and Meng S et al. (2002):** Overexpression of Apolipoprotein A-1-IV enhances lipid transport in newborn swine intestinal epithelial cells. *J Biol Chem*; 277: 31929-37.
- Lucos JF, Bradley SM, Eicher D, Sigler M and Paul T (2005):** Fatal complete atrioventricular block as a complication of bacterial sepsis in a premature newborn. *Pediatr Cardiol*; 26(5):677-9.
- Mackness MI, Durrington PN, Mackness B (2000):** How high-density lipoprotein protects against the effects of lipid peroxidation. *Curr Opin Lipidol* 11:383-388.
- Madan B and Ghosh B (2003):** Diferuloylmethane inhibits neutrophil infiltration and improves survival of mice in high-dose endotoxin shock. *Shock* 19: 91-96.
- Majcherczyk, P. A. et al (1999):** Digestion of *Streptococcus pneumoniae* cell walls with its major peptidoglycanhydrolase releases branched stem peptides carrying proinflammatory activity. *J. Biol. Chem.* 274, 12537–12543.

- Malm G, Engman ML (2007):** Congenital cytomegalovirus infections. *Semin Fetal Neonatal Med.* Jun;12(3):154-9. Epub 2007 Mar 6.
- Manucha V, Rusca U, Shik M et al. (2003):** Utility of hematological parameters and CRP detection of neonatal sepsis. *Pediatr Infect Dis J*; 125:1200-1201.
- Martin M Meremikwu, Chukwuemeka E Nwachukwu, Anne E, Asuquo, Joseph Uokebe and Simon J Utsalo (2005):** Bacterial isolates from blood cultures of children with suspected septicemia in Calabar, Nigeria. *BMC Infect*; 5:110.
- Matasova K, Hudeceva J and Zibolen M (2003):** Bilateral endogenous endophthalmitis as a complication of late-onset sepsis in a premature infants. *Eur J Pediatr*; 162(5):346-7.
- Matsunaga T, Nakajima T, Miyazaki T, Koyama I, Hokari S, Inoue I, Kawai S, Shimomura H, Katayama S, Hara A, Komoda T (2003):** Glycated high-density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells. *Metabolism* 52:42-49.
- Matz CE and Jonas A (1982):** Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. *J Biol Chem* 257:4535-4540.
- Mayes PA (1993):** Lipid transport and storage. In: *Harper's Biochemistry*. 23rd ed. Murray RK, Mayes PA, Granner DK and Rodwell VW (eds). Appleton and Lange. Ch.26; 251-76.

- McDonald MC, Dhadly P, Cockerill G, Cuzzocrea S, Hinds CJ, Miller NE, Thiemermann C (2003):** Reconstituted high density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. *Shock* 20:551-557.
- McGovern LM, Boyce TG, Fischer PR (2007):** Congenital infections associated with international travel during pregnancy. *J Travel Med.* Mar-Apr; 14(2):117-28.
- Medzhitov, R, Preston-Hurlburt, P, Janeway, CA Jr (1997):** A human homologue of the *Drosophila* Tollprotein signals activation of adaptive immunity. *Nature* 388, 394–397.
- Mehta NM, Thomas RM (2002):** Antenatal screening for rubella-infection or immunity?; *BMJ.* Jul 13; 325 (7355): 90-1.
- Memon R, Staprans I, Noor M (2000):** Infection and inflammation induce LDL oxidation in vivo. *Arterioscler Thromb Vasc Biol* 20:1536-1542.
- Merk (2002):** Neonatal infections in: *The Merk Manual of Diagnosis and Therapy* Section19.Pediatrics Chapter 260.
- Michel, T, Reichhart, JM, Hoffmann, JA, Royet, J (2001):** *Drosophila* Toll is activated by Gram-positivebacteria through a circulating peptidoglycan recognition protein. *Nature* 414, 756–759.
- Millar CG and Thiemermann C (2002):** Carboxy-PTIO, a scavenger of nitric oxide, selectively inhibits the increase in medullary perfusion and improves renal function in endotoxemia. *Shock* 18:64-68.

- Miller GJ and Miller NE (1975):** Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16-19.
- Minussi L, Mohrdieck R, Bercini M, et al. (2008):** Prospective evaluation of pregnant women vaccinated against rubella in southern Brazil. Reprod Toxicol. Jan; 25(1):120-3. Epub 2007 Sep 16
- Moncada S and Higgs A (1993):** The l -arginine-nitric oxide pathway. N Engl J Med 329:2002-2012.
- Moncada S and Higgs A (1995):** Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 9:1319-1330.
- Moore K W, De Waal and Malefyt R (2001):** Interleukin-10 and The Interleukin-10 receptor. Ann. Rev. Immunol; 19: 638-765.
- Morath, S, Geyer, A and Hartung, T (2001):** Structure–function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 193, 393–397.
- Moses TT (2005):** Neonatal sepsis. Family Practice Note book, LLC; Chapter, 87:4701-4703.
- Mosnier LO, Gale AJ, Yegneswaran S and Griffin JH (2004):** Activated Protein C Variants with normal cytoprotective but reduced anticoagulant activity. Blood 104(6): 1740-4.
- Moudry R, Spycher MO, Doran JE (1997):** Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 7:175-181.

- Muller-Alouf, H et al. (2001):** Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenessuperantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A. *Infect. Immun.* 69, 4141–4145.
- Nagai, Y et al. (2002):** Essential role of MD-2 in LPS responsiveness and TLR4 distribution. *Nature Immunol.* 3, 667–672.
- Nanjee MN, Doran JE, Lerch PG, Miller NE (1999):** Acute effects of intravenous infusion of apolipoprotein A-I/phosphatidylcholine discs on plasma lipoproteins in human. *Arterioscler Thromb Vasc Biol* 19:979-989.
- Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, Macvittie TJ, Walker RI, Parrillo JE (1989):** Role of endotoxemia in cardiovascular dysfunction and mortality- Escherichia coli and S. aureus challenges in a canine model of human septic shock. *J Clin Invest* 83:243-251.
- Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, van Lenten BJ, Vora D, Fogelman AM (2001):** HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. *Arterioscler Thromb Vasc Biol* 21:481-488.
- Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM (1996):** The Yin and Yang of oxidation in the development of the fatty streak. *Arterioscler Thromb Vasc Biol* 16:831-842.

- Navab M, Hama SY, Hough GP (1998):** High density associated enzymes: their role in vascular biology. *Curr Opin Lipidol* 9:449-456.
- Navab M, Hough GP, Stevenson LW, Drinkwater DC, Laks H, Fogelman AM (1988):** Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. *J Clin Invest* 82:1853-1863.
- Nelson S and Bagby GJ (2004):** The fetus and the neonatal infant Epidemiology of Early –and Late-onset. *Neonatal infections;* (2):628.
- Netea MG, Curfs JH, Demacker PN, Meis JF, Van der Meer JW, Kullberg BJ (1999):** Infusion of lipoproteins into volunteers enhances the growth of *Candida albicans*. *Clin Infect Dis* 28:1148-1151.
- Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001):** Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. *J Biol Chem* 276:44444-44449.
- Nick J A, Coldren CD, Geraci MW, Poch KR, Fouty BW, et al (2004):** Recombinant human activated Protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. *Blood* 15; 104 (13):3878-85.

- No authors listed (2006):** What can be done about hepatitis B?; Drug Ther Bull. Jun; 44(6):41-4.
- Nonogaki K, Fuller GM, Fuentes NL (1995):** Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136:143-149.
- Nonogaki K, Moser AH, Pan XM, Staprans I, Grunfeld C, Feingold KR (1995):** Lipoteichoic acid stimulates lipolysis and hepatic triglyceride secretion in rats in vivo. J Lipid Res 36:1987-1995.
- Norrby-Teglund, A et al. (2001):** Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis. 184, 853–860 (2001).
- Okajima, K (2002):** Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev. 184, 258–274.
- Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE (1999):** Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180:1584-1589.
- Opal, SM and Huber, Ch (2002):** Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit. Care 6, 125–136.
- Ottolini M, Lungren K, Cason S et al (2003):** Utility of Complete Blood Count and Blood Culture Screening in the diagnosis of neonatal sepsis. Pediatr Infect Dis J; 17: 22-235.

Ozinsky, A et al. (2000): The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. *Proc. Natl Acad. Sci. USA* 97, 13766–13771.

Packard C, Nunn A, Hobbs R (2002): Future Forum Editorial Board: High density lipoprotein: guardian of the vascular system? *Int J Clin Pract* 56:761-771.

Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ (1997): Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. *J Exp Med* 184:1601-1608.

Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, Arnet B, van den Ende A, ten Cate JW, van Deventer SJ (1997): Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. *Thromb Haemost* 77:303-307.

Papageorgiou, AC and Acharya, KR (2000): Microbial superantigens: from structure to function. *Trends Microbiol.* 8, 369–375.

Park CT and Wright SD (1996): Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. *J Biol Chem* 271:18054-18060.

Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL (1995): Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharide in human whole blood. *Infect Immun* 63:253-258.

Patterson KB, Leone PA, Fiscus SA, et al (2007): Frequent detection of acute HIV infection in pregnant women. *AIDS*. Nov 12; 21(17):2303-8.

Pc Ng (2004): Diagnostic markers of infection in neonates. *Archives of Disease in childhood (Fetal and Neonatal Edition)*; 89: F229.

Pearson AM (1996): Scavenger receptors in innate immunity. *Curr Opin Immunol* 8:20-28.

Peters CJ, Nanjee MN, Gordon AC, Miller NE, Hinds CJ (2002): Proinflammatory modifications of lipoprotein structure and function in patients with septic shock: relationship to outcome. *ESICM (Barcelona)* S97(A).

Peterson, Meghan Michal (2010): Apolipoprotein B-mediated control of *Staphylococcus aureus* virulence

Philip A (2006): Use of C reactive Protein in minimizing antibiotics exposure in neonatal sepsis. *Pediatrics*; 106 (1): 34-45.

Pittman RC, Glass CK, Atkinson D, Small DM (1987): Synthetic high density lipoprotein particles. *J Biol Chem* 262:2435-2442.

- Poltorak, A et al. (1998):** Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282, 2085–2088.
- Prabhakar Kocherlakota and Edmund F LaGamma (1997):** Human Granulocyte Colony-Stimulating Factor may improve outcome attributable to neonatal sepsis complicated by neutropenia. *Pediatrics*; 100 (1): 6.
- Prats J A, Cooper TR, Schneider VF and Stager CF (2000):** Rapid detection of microorganisms in Blood Cultures of newborn infants. *Pediatr*; 105 (30): 523-7.
- Primo-Parmo SL, Sorenson RC, Teiber J (1996):** La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. *Genomics* 33:498-507.
- Pruzanski W, deBeer FC, deBeer MC, Stefanski E, Vadas P (1995):** Serum amyloid A protein enhances the activity of secretory phospholipase A2. *Biochem J* 309:461-464.
- Pruzanski W, Vadas P, Browning J (1993):** Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. *J Lipid Mediat* 8:161-167.
- Pugin, J et al. (1994):** CD₁₄ is a pattern recognition receptor. *Immunity* 1, 509–516.
- Rader DJ (2003):** Regulation of reverse cholesterol transport and clinical implications. *Am J Cardiol* 92:42J-49J.

- Radunovic N, Kuczynski E and Rosen T et al. (2000):** Plasma Apolipoprotein A-1₁ and B concentrations in growth-retarded fetuses, a link between low birth weight and adult atherosclerosis. *J Clin Endocrinol Metab*; 85(1): 85-8.
- Raggio MJ and Morris PE (2004):** Drotrecogin alpha. *Drugs Today (Barc)*; 40(6): 516-38.
- Raina N, Matsui J, Cunnane SC, Jeejeebhoy KN (1995):** Effect of tumor necrosis factor-alpha on triglyceride and phospholipid content and fatty acid composition of liver and carcass in rats. *Lipids* 30:713-718.
- Ramet, M, Manfrulli, P, Pearson, A, Mathey-Prevot, B, Ezekowitz, RA (2002):** Functional genomic analysis of phagocytosis and identification of a *Drosophila* receptor for *E. coli*. *Nature* 416, 644–648.
- Redgrave TG, Rakic V, Mortimer BC, Mamo JC (1992):** Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma. Studies with lipid emulsions in rats. *Biochim Biophys Acta* 1126:65-72.
- Rensen PC, de Vruet RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ (2001):** Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. *Adv Drug Deliv Rev* 47:251-276.

- Rensen PCN, Van Oosten M, Van De Bilt E, Van Eck M, Kuiper J, Van Berkel T (1997):** Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. *J Clin Invest* 99:2438-2445.
- Rice TW and Bernard GR (2004):** Drotrocogin alpha (activated) for the treatment of severe sepsis and septic shock. *Am J Med Sci*; 328 (4):205-14.
- Riedemann NC, Ward PA (2003):** Anti-inflammatory strategies for the treatment of sepsis. *Expert Opin Biol Ther* 3:339-350.
- Riewald, M, Petrovan, RJ, Donner, A, Mueller, BM, Ruf, W (2002):** Activation of endothelial cell protease activated receptor 1 by the protein C pathway. *Science* 296, 1880–1882.
- Rifai N, Bachorik S and Albers J (1999):** Lipids, lipoproteins, and apolipoproteins. In: *Tietz Textbook of Clinical Biochemistry*. 3rd ed. Burlis AC and Ashwood RE (eds.). WB Saunders Company, America, Chap.25; 809-60.
- Rigotti A, Trigatti B, Babitt J, Penman M, Xu S, Krieger M (1997):** Scavenger receptor BI: a cell surface receptor for high-density lipoprotein. *Curr Opin Lipidol* 8:181-188.
- Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M (1997):** A targeted mutation in the murine gene encoding the high-density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. *Proc Natl Acad Sci USA* 94:12610-12615.

- Rivers, E et al. (2001):** Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N. Engl.J. Med.* 345, 1368–1377.
- Roberton NRC and Rennie J M (1999):** Infection in the newborn by Dear P (ed): In *Textbook of neonatology* 3rd edition. Churchill-livingstone. 1109-1139.
- Roberts IA and Murray NA (2003):** Thrombocytopenia in the newborn. *Curr Opin Pediatr*; 15(1):17-23.
- Roberts IA and Murray NA (2006):** Neonatal thrombocytopenia. *Curr Hematol Rep*; 5(1):55-63.
- Rodwell RL, Leslie AL and Tudehope DI (1988):** Early diagnosis of neonatal sepsis using a hemtologic scoring system. *J Pediatr*; 112 (2):761-7.
- Rose JR, Mullarkey MA, Christ WJ, Hawkins LD, Lynn M, Kishi Y, Wasan KM, Peteherych K, Rossignol DP (2000):** Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. *Antimicrob Agents Chemother* 44:504-510.
- Roth RI, Levin FC, Levin J (1993):** Distribution of bacterial endotoxin in human and rabbit blood and effects of stroma-free hemoglobin. *Infect Immun* 61:3209-3215.
- Royal College of Obstretricians and Gynaecologists (2004):** Management of HIV in pregnancy.

- Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M (2003):** Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. *Free Radic Biol Med* 34:774-784.
- Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM (1991):** Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. *Nature* 353:265-267.
- Rye K.A, Clay MA, Barter PJ (1999):** Remodelling of high density lipoproteins by plasma factors. *Atherosclerosis* 145:227-238.
- Salem SY, Shriner E, Zmora E, Vardi H, Shoham-Vardi I and Mazor M (2006):** Risk factors for early neonatal sepsis. *Arch Gynecol Obstet*; 21.
- Sammalkorpi K, Valtonen V, Kerttula Y Nikkila E, Taskinen MR (1988):** Changes in serum lipoprotein pattern induced by acute infections. *Metabolism* 37:859-865.
- Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC (1990):** Structure and function of lipopolysaccharide binding protein. *Science* 249:1429-1431.
- Scott Moses (2005):** Neonatal sepsis. *Family Prctice Note book, LLC*; Chapter, 87:4701-4703.
- Seekamp A, Jochum M, Ziegler M, van Griensven M, Martin M, Regel G (1998):** Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. *J Trauma* 44:874-882.

- Segal GB (1995):** Hematology of the newborn: By Ernest B, Marshall AL, Barry SC and Thomas J k (eds): In William's Hematology 5th Edition, Philadelphia, W B Saunders, pp57:86.
- Segrest JP (2000):** Non-LDL lipid risk factors: HDL, triglycerides, small dense LDL-c and Lp(a). Clin Rev Spring; 23-8.
- Segrest JP (2002):** The role of non-LDL: Non-HDL particles in atherosclerosis. Curr Diab Rep; 2(3): 282-8.
- Seydel, U., Oikawa, M., Fukase, K., Kusumoto, S., Brandenburg, K. (2000):** Intrinsic conformation of lipidA is responsible for agonistic and antagonistic activity. Eur. J. Biochem. 267, 3032–3039.
- Sheperd C, Fisher M, Rosenstein N, et al., (2003):** Neonatal meningococcal disease in the United States. Pediat Infect Dis J; 20: 20-31.
- Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998):** Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287.
- Shimazu, R et al. (1999):** MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189, 1777–1782.
- Simons RK, Hoyt DB, Winchell RJ, Rose RM, Holbrook T (1996):** Elevated selectin levels after severe trauma: a marker for sepsis and organ failure and a potential target for immunomodulatory therapy. J Trauma 41:653-662.

Sparwasser, T et al. (1997): Bacterial DNA causes septic shock. Nature 386, 336–337.

Springer TA (1990): Adhesion receptors of the immune system. Nature; 346-425.

Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM (1997): Platelet-activating factor acetylhydrolases. J Biol Chem 272:17895-17898.

Steel DM and Whitehead AS (1994): The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15:81-88.

Stefane Barlage(2009):Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation Volume 35, Number 11, 1877-1885, DOI: 10.1007/s00134-009-1609-y

Stein EA and Gray LM (1994): Lipids, lipoproteins and apolipoproteins. In: Tietz N (ed.). Textbook of Clinical Chemistry, 2nd ed. Burtis and Ashwood ER (eds). Philadelphia: WB Saunders Co.; 1002.

Stein EA and Myers GL (1994): Lipids, lipoproteins and apolipoproteins. In: Tietz Textbook of Clinical Chemistry. 5th ed. Edward R and Ashwood (eds). WB Saunders Company; 1019-32.

- Stein EA and Myers GL (1994):** Lipids, lipoproteins and apolipoproteins. In: Tietz Textbook of Clinical Chemistry. 5th ed. Edward R and Ashwood (eds). WB Saunders Company; 1019-32.
- Steinbrecher UP and Pritchard PH (1989):** Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 30:305-315.
- Stiles BG, Bavari S, Krakauer T, Ulrich RG (1993):** Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect Immun 61:5333-5338.
- Stoll B: Infections in Neonates: Etiology of Fetal and Neonatal Infection.** In: Nelson Text Book of Pediatrics, 18th ed., Kliegman, Beharman, Janson & Stanton (eds.); Sanders; Philadelphia, USA, Chapter 109, pp. 794-811, 2008.
- Stuber, F (2001):** Effects of genomic polymorphisms on the course of sepsis: is there a concept for genetherapy? J. Am. Soc. Nephrol. 12 (Suppl. 17), S60–S64.
- Suurkuusk M and Singh SK (2000):** Formation of HDL-like complexes from apolipoprotein A-I (M) and DMPC. Int J Pharm 194:21-38.
- Szabo C and Thiemermann C (1994):** Invited opinion: Role of nitric oxide in hemorrhagic, traumatic, and anaphylactic shock and thermal injury. Shock 2:145-155, 1994.

- Szymankiewicz M, Oszkinis G and Uchman J (2005):** Abdominal aortic-iliac thrombosis as a complication of newborn's bacterial sepsis. *Grinekol Pol*; 76(1): 61-6.
- Takeuchi, O et al. (1999):** Differential roles of TLR2 and TLR4 in recognition of gram-negative and grampositivebacterial cell wall components. *Immunity* 11, 443–451.
- Tall AR (1990):** Plasma high-density lipoproteins: metabolism and relationship to atherogenesis. *J Clin Invest* 86:379-384.
- Thiemermann C (1997):** Nitric oxide and septic shock. *Gen Pharmac* 29:159-166.
- Thiemermann C (2001):** Aminoethyl-Isothiourea in Gram-positive shock: an inhibitor of inducible nitric oxide synthase or a Jack-of-all-trades? *Shock* 15:453-454.
- Thiemermann C, Patel NS, Kvale EO, Cockerill GW, Brown PA, Stewart KN, Cuzzocrea S, Britti D, Mota-Filipe H, Chatterjee PK (2003):** High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. *J Am Soc Nephrol* 14:1833-1843.
- Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ (2002):** Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. *Arterioscler Thromb Vasc Biol* 22:1213-1218.

- Tobias PS and Ulevitch RJ (1983):** Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). *J Immunol* 131:1913-1916.
- Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lulis AJ, Shih DM (2002):** Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. *Circulation* 106:484-490.
- Unnikrishnan, M et al. (2002):** The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of *Streptococcus pyogenes*. *J. Immunol.* 169, 2561–2569.
- Van Amersfoort ES, Van Berkel TJ, Kuiper J (2003):** Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. *Clin Microbiol Rev* 16:379-414.
- Van den Berghe, G et al. (2001):** Intensive insulin therapy in critically ill patients. *N. Engl. J. Med.* 345, 1359–1367.
- Van der Poll, T, de Jonge, E, Levi, M, van Deventer, SJ (1999):** Pathogenesis of DIC in sepsis. *Sepsis* 3, 103–110.
- van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP (2003):** Lipoprotein metabolism in patients with severe sepsis. *Crit Care Med* 31:1359-1366.
- van Leeuwen HJ, van Beek AP, Dallinga-Thie GM, van Strijp JAG, Verhoef J, van Kessel KPM (2001):** The role of high density lipoprotein in sepsis. *Neth J Med* 59:102-110.

- van Leeuwen PA, Boermeester MA, Houdijk AP, Ferwerda CC, Cuesta MA, Meyer S, Wesdorp RI (1994):** Clinical significance of translocation. *Gut* 35:S28-S34.
- Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA (1986):** The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. *Proc Natl Acad Sci USA* 83:2704-2708.
- van Lenten BJ, Hama SY, de Beer FC (1995):** Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. *J Clin Invest* 96:2758-2767.
- Van Oosten M, Rensen PCN, Van Amersfoort ES, Van Eck M, Van Dam AM, Brevé P, Vogel T, Panet A, van Berkel TJC, Kuiper J (2001):** Apolipoprotein protects against bacterial lipopolysaccharide-induced lethality: a new therapeutic approach to treat gram-negative sepsis. *J Biol Chem* 276:8820-8824.
- Vartzelis G, Theodoridou M, Daikos G L, Dellagrammaticas H and Syriopoulou VP (2005):** Brain abscesses complicating staphylococcus aureus sepsis in a premature infant. *Infection*; 33(1): 36-8.
- Vasselon, T and Detmers, PA (2002):** Toll receptors: a central element in innate immune responses. *Infect. Immun.* 70, 1033.

- Vesey CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS (2000):** Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from gram-negative bacterial membranes. *Infect Immun* 68:2410-2417.
- Viscoli C, Castagnola E, Giacchino M, Cesaro S, Properzi E, Tucci F, Mura RM, Alvisi P, Zanazzo G, Surico G, Bonetti F, De Sio L, Izzi G, Di Cataldo A, Ziino O, Massolo F, Nardi M, Santoro N, Binda S (1999):** Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. *Eur J Cancer* 35:770-774.
- Volmink J, Siegfried NL, van der Merwe L, et al. (2007):** Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD003510.
- Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, van 't Veer C, Buurman WA (2003):** Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. *J Immunol* 170:1399-1405.
- Vreugdenhil ACE, Snoek AM: van't Veer C, Greve JW, Buurman WA (2001):** LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. *J Clin Invest* 107:225-234.

Wu A, Hinds CJ, Thiernemann C: *Shock*. 2004 Mar; 21 (3):210- 21.
PMID: 14770033 [PubMed - indexed for MEDLINE].

Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA (1991): S. epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock like state and tissue injury in rabbits without endotoxemia-comparison to Escherichia coli. *J Clin Invest* 87:1925-1935.

Walker DG and Walker GJ (2002): Forgotten but not gone: the continuing scourge of congenital syphilis. *Lancet Infect Dis*. Jul;2(7):432-6.

Walmsley RN and White GH (1994): Plasma lipids. In: A guide to diagnostic clinical chemistry. 3rd ed. Walmsley RN and White GH (eds.). Oxford, Blackwell Scientific Publication, Chap.13; 348-67.

Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiernemann C (2003): Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. *Shock* 20:402-414.

Wang JE, Jorgensen PF, Ellingsen EA, Almiof M, Thiernemann C, Foster SJ, Aasen AO, Solberg R (2001): Peptidoglycan primes for LPS-induced release of proinflammatory cytokines in whole human blood. *Shock* 16:178-182.

- Wang, H et al. (1999):** HMG-1 as a late mediator of endotoxin lethality in mice. *Science* 285, 248–251.
- Wang, J. E. et al. (2000):** Peptidoglycan and lipoteichoic acid from *Staphylococcus aureus* induce tumornecrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. *Infect. Immun.* 68, 3965–3970.
- Warnick RG, McNamara RJ and Wu LL (1996):** Lipids and lipoproteins. In: *Clinical Chemistry Principles, Procedures and Correlations*. 3rd ed. Bisphop ML, Duben, Engrelkirk JL and Fody EP (eds.). Lippincott-Raven Publishers, Philadelphia and New York, Chap.15; 313-33.
- Warrell D, Cox TM, Firth JD, Benz E (2004):** *Oxford Textbook of Medicine*, 4th ed. OUP. ISBN 0198529988.
- Wasan KM, Strobel FW, Parrott SC, Lynn M, Christ WJ, Hawkins LD, Rossignol DP (1999):** Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. *Antimicrob Agents Chemother* 43:2562-2564.
- Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, Ryan RO (2003):** Structure and interfacial properties of human apolipoprotein A-V. *J Biol Chem* 278:34438-34444.

- Werner, T et al. (2000):** A family of peptidoglycan recognition proteins in the fruit fly *Drosophila melanogaster*. *Proc. Natl Acad. Sci. USA* 97, 13772–13777.
- Wheeler AP, Bernard GR (1999):** Treating patients with severe sepsis. *N Engl J Med* 340:207-214.
- Wray GM, Foster SJ, Hinds CJ, Thiemermann C (2001):** A cell wall component from pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumor necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. *Shock* 15:135-142.
- Wray GM, Millar CG, Hinds CJ, Thiemermann C (1998):** Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. *Shock* 9:329-335.
- Wright, SD, Ramos, RA, Tobias, PS, Ulevitch, RJ, Mathison, JC (1990):** CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science* 249, 1431–1433.
- Wu LH, Wu JT and Hopkins PN (1994):** Apolipoprotein E. Laboratory determination and clinical significance. In: *Methods for Clinical Laboratory Measurement of Lipid and Lipoprotein Risk factors*. 2nd ed. Rifai N, Warnick GR (eds.). Washington, DC, AACC Press; 279.

- Wurfel MM, Hailman E, Wright SD (1995):** Soluble CD₁₄ acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. *J Exp Med* 181:1743-1754.
- Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD (1994):** Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. *J Exp Med* 180:1025-1035.
- Xu XX, Tabas I (1991):** Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. *J Biol Chem* 266:24849-24858.
- Yamagishi S, Abe T, Sawada T (1994):** Human recombinant interferon alpha-2a (r IFN alpha-2a) therapy suppresses hepatic triglyceride lipase, leading to severe hypertriglyceridemia in a diabetic patient. *Am J Gastroenterol* 89:2280.
- Yang, H, Wang, H, Tracey, KJ (2001):** HMG-1 rediscovered as a cytokine. *Shock* 15, 247–253.
- Yildiz B, Ucar B, Aksit a, Aydogdu SD, Colak O, and Colak E:** Diagnostic values of Lipid and Lipoprotein Levels in Late Onset Neonatal sepsis. *Scand J Infect Dis*, Feb 17: 1-6, 2009.
- Yu, B, Hailman, E, Wright, SD (1997):** Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. *J. Clin. Invest.* 99, 315–324.